title: Effect of Infliximab and Adalimumab on Experimental Colitis Following Orally Supplemented Iron.
abstract: BACKGROUND
  Orally administered iron can induce colonic inflammation in healthy animals and aggravate experimental colitis.
  
  
  OBJECTIVE
  To investigate the influence of the biologic agents infliximab and adalimumab on the severity of TNBS colitis following orally supplemented iron.
  
  
  METHODS
  204 Wistar rats were allocated into 14 groups. Colitis was induced by TNBS. Iron was administered via a mouth catheter at a dose of 0.027, 0.3, and 3%/kg diet per day, respectively. Infliximab was subcutaneously administered on the 2ndand 6thday in a dose of 5 mg/kgBW, while adalimumab was administered on the 2ndday in a dose of 2 mg/kgBW. On the 8thday, all animals were euthanatized. Activity of colitis and extent of tissue damage were assessed histologically. Tissue Tumor Necrosis Factor-α (t-TNF-α) and malondialdehyde (t-MDA) were estimated.
  
  
  RESULTS
  In normal rats both agents significantly worsen the degree of inflammation induced by moderate or high iron supplementation despite the disappearance of t-TNF-α, and reduction of t-MDA. In the groups of TNBS colitis and moderate or high iron administration, both agents again significantly worsen the degree of inflammation despite the significant reduction in the t-TNF-α and t-MDA.
  
  
  CONCLUSIONS
  Adalimumab and infliximab do not ameliorate the inflammation in TNBS-induced colitis aggravated by orally administered iron. These findings might be clinically relevant in patients with active IBD under concurrent treatment with biologic agents and per oral iron.
authors.affiliation: a Inflammatory Bowel Disease Unit, "IASO General" Hospital , Athens , Greece.
authors.forename: John
authors.initials: J
authors.lastname: Triantafillidis
authors.affiliation: b Inflammatory Bowel Disease Unit, "IASO General" Hospital , Holargos, Athens , Greece.
authors.forename: Costas
authors.initials: C
authors.lastname: Vagianos
authors.affiliation: c Department of Pathology , University of Athens Medical School , Athens , Greece.
authors.forename: George
authors.initials: G
authors.lastname: Agrogiannis
authors.affiliation: d Health Center of Kalivia , Kalivia , Attiki , Greece.
authors.forename: Aristofanis
authors.initials: A
authors.lastname: Gikas
authors.affiliation: a Inflammatory Bowel Disease Unit, "IASO General" Hospital , Athens , Greece.
authors.forename: Georgia
authors.initials: G
authors.lastname: Douvi
authors.affiliation: e Aristotle University of Thessaloniki School of Medicine , Thessaloniki , Greece.
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Syrmos
authors.affiliation: f University of Athens, School of Medicine , Athens , Greece.
authors.forename: Efstratios
authors.initials: E
authors.lastname: Patsouris
authors.affiliation: g Experimental - Research Center ELPEN Pharmaceuticals , Athens , Greece.
authors.forename: Apostolos
authors.initials: A
authors.lastname: Papalois
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use*; D000740:Anemia / Q000188:drug therapy; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D003106:Colon / Q000378:metabolism; D004195:Disease Models, Animal; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000139:chemically induced / Q000188:drug therapy*; D000069285:Infliximab / Q000627:therapeutic use*; D007413:Intestinal Mucosa / Q000187:drug effects; D007501:Iron / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D014302:Trinitrobenzenesulfonic Acid / Q000633:toxicity; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D000893:Anti-Inflammatory Agents; D014409:Tumor Necrosis Factor-alpha; D008315:Malondialdehyde; D014302:Trinitrobenzenesulfonic Acid; D000069285:Infliximab; D007501:Iron; D000068879:Adalimumab
keywords: Crohn's disease; adalimumab; anemia; biologic agents; experimental colitis; inflammatory bowel disease; infliximab; iron; ulcerative colitis